Genmab regains HuMax-CD4 rights

Denmark's Genmab has regained the rights to the antibody Humax-CD4 from Merck Serono. Genmab granted Merck Serono worldwide rights to develop and market Humax-CD4, which is used for treatment of T-cell lymphomas, an immune system related cancer form, two years ago. The company says it will continue the development of the antibody and will further work targeting the CD4 receptor as a mechanism to prevent or slow HIV infection.

"We are very enthusiastic about having HuMax-CD4 back in the hands of Genmab's experienced clinical development team," said Genmab chief executive Lisa N. Drakeman.

- check out Genmab's release
- here's the report from Hemscott

Related Articles:
Glaxo forges $2.1B deal for HuMax-CD20. Report
Genmab touts positive trial data. Report 

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.